Molecular mechanisms for the antidepressant-like effects of a low-dose ketamine treatment in a DFP-based rat model for Gulf War Illness

Neurotoxicology. 2020 Sep:80:52-59. doi: 10.1016/j.neuro.2020.06.011. Epub 2020 Jun 24.

Abstract

Exposure to organophosphates (OP) during the First Gulf War is among one of the factors for Gulf War Illness (GWI) development in veterans and it has been challenging to treat GWI symptoms with existing therapies. Ketamine produces a rapid-onset and sustained antidepressant response, but there is no evidence whether ketamine treatment is effective for GWI depression. Repeated, low-dose exposure to diisopropyl fluorophosphate (DFP) mimic Gulf War related OP exposures and produces a chronic depressive state in rats. In this study, DFP-exposed rats treated with ketamine (10 mg/kg, i.p.) exhibited antidepressant-like effect on the Forced Swim Test at 1-h. This effect persisted at 24-h post ketamine, a time-point by which it is eliminated from the brain suggesting involvement of mechanisms that affect long-term synaptic plasticity. Western blot analysis showed significantly lower Brain-Derived Neurotrophic Factor (BDNF) levels in DFP rat brains. Ketamine produced a nonsignificant increase in BDNF expression at 1-h but produced a larger, significant (2.2-fold) increase at 24-h in DFP rats. We previously reported chronic hippocampal calcium elevations ([Ca2+]i) in DFP rats. Ketamine-treated DFP rats exhibited significantly lower [Ca2+]i at 1-h but not at 24-h. Interestingly, treatment with ANA-12, a TrkB-BDNF receptor antagonist, in DFP rats blunted ketamine's antidepressant-like effect at 24-h but not at 1-h. These experiments suggest that in a rat model of DFP-induced depression, inhibition of the NMDAR-Ca2+ contributes to the rapid-onset antidepressant effects of ketamine while the antidepressant actions that persisted at 24-h post ketamine administration involve upregulation of BDNF signaling.

Keywords: BDNF; DFP; Organophosphates; Sprague-Dawley rats; calcium dynamics; depression; ketamine; memantine.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antidepressive Agents* / pharmacology
  • Behavior, Animal* / drug effects
  • Brain* / drug effects
  • Brain* / metabolism
  • Brain* / physiopathology
  • Brain-Derived Neurotrophic Factor / metabolism
  • Calcium Signaling / drug effects
  • Depression* / chemically induced
  • Depression* / drug therapy
  • Depression* / metabolism
  • Depression* / psychology
  • Disease Models, Animal
  • Excitatory Amino Acid Antagonists* / pharmacology
  • Ketamine* / pharmacology
  • Locomotion / drug effects
  • Male
  • Persian Gulf Syndrome* / chemically induced
  • Persian Gulf Syndrome* / drug therapy
  • Persian Gulf Syndrome* / metabolism
  • Persian Gulf Syndrome* / psychology
  • Rats, Sprague-Dawley
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • Receptors, N-Methyl-D-Aspartate / metabolism
  • Time Factors

Substances

  • Antidepressive Agents
  • Bdnf protein, rat
  • Brain-Derived Neurotrophic Factor
  • Excitatory Amino Acid Antagonists
  • Ketamine
  • Receptors, N-Methyl-D-Aspartate